6-K: Us Fda Accepts for Priority Review Gsk's Application for an Expanded Indication of Jemperli Plus Chemotherapy to Include All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer
Apr 24 06:48 ET
6-K: Transaction Notification
Apr 19 10:59 ET
6-K: Transaction Notification
Apr 17 10:54 ET
6-K: New Long-Term Data Show Shingrix Continues to Provide High Protection Against Shingles in Adults Aged 50 and over for More Than a Decade
Apr 17 06:14 ET
6-K: Gsk Today Announced Positive Results from the Pivotal Eagle-1 Phase Iii Trial for Gepotidacin
Apr 17 06:09 ET
6-K: The Following Amendments Have Been Made in Accordance with the “director/Pdmr Shareholdings” Announcement Issued by Rns No 6709k
Apr 16 09:55 ET
6-K: GSK's 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
Apr 16 06:24 ET
GlaxoSmithKline | 6-K: Transaction Notification
Apr 15 11:29 ET
GlaxoSmithKline | 6-K/A: Total Voting Rights and Capital
Apr 4 07:50 ET
GlaxoSmithKline | 6-K: Total Voting Rights and Capital
Apr 2 13:20 ET
GlaxoSmithKline | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-GSK plc(4.5%)
Mar 28 17:11 ET
GlaxoSmithKline | 6-K: Transaction Notification
Mar 26 07:49 ET
GlaxoSmithKline | F-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Mar 25 14:04 ET
GlaxoSmithKline | 6-K: GlaxoSmithKline releases notice of 2024 Annual General Meeting of Shareholders
Mar 25 09:43 ET
GlaxoSmithKline | 6-K: Transfer of Treasury Shares
Mar 22 12:52 ET
GlaxoSmithKline | 6-K: Transaction Notification
Mar 22 12:22 ET
GlaxoSmithKline | 6-K: Positive Ruby Phase Iii Data Show Potential for Jemperli (Dostarlimab) Combinations in More Patients with Primary Advanced or Recurrent Endometrial Cancer
Mar 18 09:59 ET
GlaxoSmithKline | 6-K: Transaction Notification
Mar 13 13:19 ET
GlaxoSmithKline | 6-K: Dr Hal Dietz Has Been Appointed a Member of the Nominations & Corporate Governance Committee
Mar 8 12:50 ET
GlaxoSmithKline | 6-K: Gsk Announces Positive Results from Dreamm-8 Phase Iii Trial for Blenrep Versus Standard of Care Combination in Relapsed/Refractory Multiple Myeloma
Mar 7 06:14 ET
No Data
No Data